R Tyler Hillman1, Douglas I Lin2, Barrett Lawson3, David M Gershenson4. 1. Department of Gynecologic Oncology and Reproductive Medicine, The University of Texas MD Anderson Cancer Center, Houston, TX, USA; Department of Genomic Medicine, The University of Texas MD Anderson Cancer Center, Houston, TX, USA. Electronic address: rthillman@mdanderson.org. 2. Foundation Medicine, Inc, Cambridge, MA, USA. 3. Department of Pathology, The University of Texas MD Anderson Cancer Center, Houston, TX, USA. 4. Department of Gynecologic Oncology and Reproductive Medicine, The University of Texas MD Anderson Cancer Center, Houston, TX, USA.
Abstract
OBJECTIVE: The objective of this study was to determine the prevalence of predictive biomarkers associated with FDA-approved therapies in molecularly defined adult-type ovarian granulosa cell tumors (aGCTs). METHODS: We performed a retrospective cross-sectional cohort study of tumor profiles using the inclusion criteria of molecularly defined (FOXL2 c.C402G positive) aGCTs previously sequenced at Foundation Medicine, Inc. The dataset included coding variants for up to 406 genes, microsatellite instability, tumor mutational burden, and genomic loss of heterozygosity (gLOH). PD-L1 expression was determined using the tumor proportion score, as measured using the DAKO 22C3 immunohistochemistry assay. RESULTS: 423 tumor profiles met inclusion criteria. The median age at the time of sample submission was 57 years (interquartile range 48-65). The mean tumor mutational burden was 1.8 mutations per megabase (range 0-8.8). No tumors exhibited microsatellite instability, and none were gLOH-High (≥16%). Sixty-seven tumors had PD-L1 expression measurement, and 94% were negative. Potentially actionable variants including MTAP deletion (12/173, 5.8%) and activating PIK3CA mutations (23/423, 5.4%) were identified. TP53-mutated aGCT had a higher tumor mutational burden (mean 2.4 mut/Mb, 95% CI 1.7-3.0 mut/Mb vs mean 1.7 mut/Mb, 95% CI 1.5-1.9 mut/Mb; P = .02) and higher gLOH score (mean 4.4%, 95% CI 2.7-6.1% vs mean 1.4%, 95% CI 1.2-1.6%; P = .002) than TP53 non-mutated tumors. CONCLUSIONS: No women with molecularly defined aGCT in this large cohort would be eligible for FDA-approved pembrolizumab based on either microsatellite instability or high tumor mutational burden. TP53 mutation identified a subset of this tumor type with distinct molecular features. The development of precision treatment options remains a critical unmet need for this rare disease.
OBJECTIVE: The objective of this study was to determine the prevalence of predictive biomarkers associated with FDA-approved therapies in molecularly defined adult-type ovarian granulosa cell tumors (aGCTs). METHODS: We performed a retrospective cross-sectional cohort study of tumor profiles using the inclusion criteria of molecularly defined (FOXL2 c.C402G positive) aGCTs previously sequenced at Foundation Medicine, Inc. The dataset included coding variants for up to 406 genes, microsatellite instability, tumor mutational burden, and genomic loss of heterozygosity (gLOH). PD-L1 expression was determined using the tumor proportion score, as measured using the DAKO 22C3 immunohistochemistry assay. RESULTS: 423 tumor profiles met inclusion criteria. The median age at the time of sample submission was 57 years (interquartile range 48-65). The mean tumor mutational burden was 1.8 mutations per megabase (range 0-8.8). No tumors exhibited microsatellite instability, and none were gLOH-High (≥16%). Sixty-seven tumors had PD-L1 expression measurement, and 94% were negative. Potentially actionable variants including MTAP deletion (12/173, 5.8%) and activating PIK3CA mutations (23/423, 5.4%) were identified. TP53-mutated aGCT had a higher tumor mutational burden (mean 2.4 mut/Mb, 95% CI 1.7-3.0 mut/Mb vs mean 1.7 mut/Mb, 95% CI 1.5-1.9 mut/Mb; P = .02) and higher gLOH score (mean 4.4%, 95% CI 2.7-6.1% vs mean 1.4%, 95% CI 1.2-1.6%; P = .002) than TP53 non-mutated tumors. CONCLUSIONS: No women with molecularly defined aGCT in this large cohort would be eligible for FDA-approved pembrolizumab based on either microsatellite instability or high tumor mutational burden. TP53 mutation identified a subset of this tumor type with distinct molecular features. The development of precision treatment options remains a critical unmet need for this rare disease.
Authors: Sohrab P Shah; Martin Köbel; Janine Senz; Ryan D Morin; Blaise A Clarke; Kimberly C Wiegand; Gillian Leung; Abdalnasser Zayed; Erika Mehl; Steve E Kalloger; Mark Sun; Ryan Giuliany; Erika Yorida; Steven Jones; Richard Varhol; Kenneth D Swenerton; Dianne Miller; Philip B Clement; Colleen Crane; Jason Madore; Diane Provencher; Peter Leung; Anna DeFazio; Jaswinder Khattra; Gulisa Turashvili; Yongjun Zhao; Thomas Zeng; J N Mark Glover; Barbara Vanderhyden; Chengquan Zhao; Christine A Parkinson; Mercedes Jimenez-Linan; David D L Bowtell; Anne-Marie Mes-Masson; James D Brenton; Samuel A Aparicio; Niki Boyd; Martin Hirst; C Blake Gilks; Marco Marra; David G Huntsman Journal: N Engl J Med Date: 2009-06-10 Impact factor: 91.245
Authors: Jie He; Omar Abdel-Wahab; Michelle K Nahas; Kai Wang; Raajit K Rampal; Andrew M Intlekofer; Jay Patel; Andrei Krivstov; Garrett M Frampton; Lauren E Young; Shan Zhong; Mark Bailey; Jared R White; Steven Roels; Jason Deffenbaugh; Alex Fichtenholtz; Timothy Brennan; Mark Rosenzweig; Kimberly Pelak; Kristina M Knapp; Kristina W Brennan; Amy L Donahue; Geneva Young; Lazaro Garcia; Selmira T Beckstrom; Mandy Zhao; Emily White; Vera Banning; Jamie Buell; Kiel Iwanik; Jeffrey S Ross; Deborah Morosini; Anas Younes; Alan M Hanash; Elisabeth Paietta; Kathryn Roberts; Charles Mullighan; Ahmet Dogan; Scott A Armstrong; Tariq Mughal; Jo-Anne Vergilio; Elaine Labrecque; Rachel Erlich; Christine Vietz; Roman Yelensky; Philip J Stephens; Vincent A Miller; Marcel R M van den Brink; Geoff A Otto; Doron Lipson; Ross L Levine Journal: Blood Date: 2016-03-10 Impact factor: 22.113
Authors: Jubilee Brown; Hyun S Shvartsman; Michael T Deavers; Lois M Ramondetta; Thomas W Burke; Mark F Munsell; David M Gershenson Journal: Gynecol Oncol Date: 2005-05 Impact factor: 5.482
Authors: Elizabeth M Swisher; Kevin K Lin; Amit M Oza; Clare L Scott; Heidi Giordano; James Sun; Gottfried E Konecny; Robert L Coleman; Anna V Tinker; David M O'Malley; Rebecca S Kristeleit; Ling Ma; Katherine M Bell-McGuinn; James D Brenton; Janiel M Cragun; Ana Oaknin; Isabelle Ray-Coquard; Maria I Harrell; Elaina Mann; Scott H Kaufmann; Anne Floquet; Alexandra Leary; Thomas C Harding; Sandra Goble; Lara Maloney; Jeff Isaacson; Andrew R Allen; Lindsey Rolfe; Roman Yelensky; Mitch Raponi; Iain A McNeish Journal: Lancet Oncol Date: 2016-11-29 Impact factor: 41.316
Authors: Mansoor R Mirza; Bradley J Monk; Jørn Herrstedt; Amit M Oza; Sven Mahner; Andrés Redondo; Michel Fabbro; Jonathan A Ledermann; Domenica Lorusso; Ignace Vergote; Noa E Ben-Baruch; Christian Marth; Radosław Mądry; René D Christensen; Jonathan S Berek; Anne Dørum; Anna V Tinker; Andreas du Bois; Antonio González-Martín; Philippe Follana; Benedict Benigno; Per Rosenberg; Lucy Gilbert; Bobbie J Rimel; Joseph Buscema; John P Balser; Shefali Agarwal; Ursula A Matulonis Journal: N Engl J Med Date: 2016-10-07 Impact factor: 91.245
Authors: Zachary R Chalmers; Caitlin F Connelly; David Fabrizio; Laurie Gay; Siraj M Ali; Riley Ennis; Alexa Schrock; Brittany Campbell; Adam Shlien; Juliann Chmielecki; Franklin Huang; Yuting He; James Sun; Uri Tabori; Mark Kennedy; Daniel S Lieber; Steven Roels; Jared White; Geoffrey A Otto; Jeffrey S Ross; Levi Garraway; Vincent A Miller; Phillip J Stephens; Garrett M Frampton Journal: Genome Med Date: 2017-04-19 Impact factor: 11.117
Authors: Jessica A Pilsworth; Dawn R Cochrane; Samantha J Neilson; Bahar H Moussavi; Daniel Lai; Aslı D Munzur; Janine Senz; Yi Kan Wang; Sina Zareian; Ali Bashashati; Adele Wong; Jacqueline Keul; Annette Staebler; Hannah S van Meurs; Hugo M Horlings; Stefan Kommoss; Friedrich Kommoss; Esther Oliva; Anniina Em Färkkilä; Blake Gilks; David G Huntsman Journal: J Pathol Clin Res Date: 2021-01-11
Authors: Alicia León-Castillo; Stephanie M de Boer; Melanie E Powell; Linda R Mileshkin; Helen J Mackay; Alexandra Leary; Hans W Nijman; Naveena Singh; Pamela M Pollock; Paul Bessette; Anthony Fyles; Christine Haie-Meder; Vincent T H B M Smit; Richard J Edmondson; Hein Putter; Henry C Kitchener; Emma J Crosbie; Marco de Bruyn; Remi A Nout; Nanda Horeweg; Carien L Creutzberg; Tjalling Bosse Journal: J Clin Oncol Date: 2020-08-04 Impact factor: 44.544